Dear Colleagues,

Mitochondria have recently developed as a key organelle and regulate cellular functions including cell proliferation or differentiation, cell death, metabolism, and cellular signaling, considered for inflammation-mediated diseases. Mitochondrial-evolved ROS has been implicated as a mediator for redox signaling, thereby causing stimulation of inflammatory proteins followed by mitochondrial deterioration and oxidative stress. Due to this kind of oxidative damage, chronic inflammation is believed to provoke several chronic diseases, including cancer and neurodegenerative disorders. In recent years, a promising insight into mitochondria-mediated cell death and inflammation has shed light on the molecular signature of the signaling machinery that could mediate different cascades of cell death and multiple kinds of inflammatory responses in chronic disease. Impairment of mitochondria-mediated anti-inflammatory machinery could cause an aggregation of unhealthy cellular components, followed by mitochondria-mediated cell death and its related episodes. To eradicate such cellular issues, and to explore whether novel strategies may be challenging therapeutic interventions, enriched delivery of the drugs and/or molecules to the impaired cells of patients with mitochondria-mediated chronic disorder is warranted. This Special Issue of Biomedicines aims to collect the original research articles and comprehensive reviews considering probable significance or impacts of pharmacotherapeutics on mitochondria-mediated inflammation and its mediated disease resistance in scientific community and healthcare settings.

Dr. Mohammad Waseem
Dr. Nemat Ali
Dr. Abdullah F. AlAsmari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• mitochondrial dysfunction
• inflammatory response
• chronic disorder
• cell death
• novel drugs
• pharmacological intervention
• cancer
• neurodegenerative disorder